Advances in the treatment of anxiety: targeting glutamate.
Our current psychopharmacological treatments for anxiety disorders evince a number of shortcomings, including troublesome side effects and lack of primary effects. Whereas many new drugs have been developed in the past few decades, most are based on outmoded theories of the pathogenesis of these disorders (i.e., monoamine hypotheses), thus frustrating our ability to create more specific and effective interventions. Recently, however, the neurobiological literature has shown a convergence of findings focusing on the glutamatergic system in anxiety disorders, and the growth of pharmacological tools targeting these receptors has led to the development of novel treatments having anxiolytic effects in humans and animals alike. Additionally, as this system is showing promise as a final common pathway in the pathogenesis of anxiety disorders, we may be able to employ glutamate-specific neuroimaging techniques (e.g., N-acetyl-aspartate, GLX) to both guide treatment decisions and present reliable objective biomarkers for treatment efficacy.
Mount Sinai School of Medicine, Department of Psychiatry, Laboratory of Clinical Psychobiology, New York, New York 10029, USA. asher.simon@mssm.edu
Asher B
AB
Simon
Jack M
JM
Gorman
D000928:Antidepressive Agents / Q000627:therapeutic use; D001007:Anxiety / Q000188:drug therapy / Q000503:physiopathology* / Q000628:therapy*; D001008:Anxiety Disorders / Q000188:drug therapy / Q000503:physiopathology* / Q000628:therapy; D018698:Glutamic Acid / Q000502:physiology*; D006801:Humans; D018094:Receptors, Metabotropic Glutamate / Q000187:drug effects / Q000502:physiology; D013315:Stress, Psychological / Q000503:physiopathology
D000928:Antidepressive Agents; D018094:Receptors, Metabotropic Glutamate; D018698:Glutamic Acid